Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth Raises $15.4 Million in Private Stock Offering

NEW YORK (GenomeWeb) – MdxHealth announced today that it has raised €12.3 milllion ($15.4 million) in a private placement. The firm sold 3.4 million shares at €3.60 per share to a group of institutional, qualified and professional investors.

"In combination with our existing cash position, these funds allow us to support and scale up MDxHealth's US-based managed care and related healthcare reimbursement efforts," Jan Groen, CEO of MDxHealth, said in a statement. "In addition, it will allow us to accelerate product development and finance general corporate purposes."

Petercam was the sole lead manager and book runner in the placement.

The announcement comes a day after MDxHealth reported Q3 revenues were up 78 percent year over year, driven by growth in its prostate cancer molecular diagnostic test, ConfirmMDx. It also announced the private placement on Tuesday.

MDxHealth is a molecular diagnostics company with offices in Herstal, Belgium and Irvine, Calif., and develops epigenetic tests for cancer assessment.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.